# A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

> **NCT01320085** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 183 (actual)

## Conditions studied

- BRAF or NRAS Mutant Metastatic Melanoma

## Interventions

- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT01320085
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-24
- **Primary completion:** 2014-01-07
- **Final completion:** 2023-02-06
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320085, "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01320085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*